Navigation Links
Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
Date:2/26/2013

CARLSBAD, Calif., Feb. 26, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-CRPRx in patients with paroxysmal atrial fibrillation. Atrial fibrillation (AF) involves an irregular and often rapid heart rate that commonly causes poor blood flow to the body.  Paroxysmal AF is a type of AF characterized by unpredictable episodes of AF that can occur as frequently as every day. Patients with AF can experience chest palpitations, chest pain, weakness and decreased blood pressure during an event. While the cause of paroxysmal AF is not known, elevated levels of CRP are associated with an increase in the severity of AF episodes. ISIS-CRPRx is being evaluated in patients with AF to measure the effect of lowering CRP on the frequency and duration of the episodes.

"CRP is elevated in many inflammatory disorders and can also be elevated in diseases with inflammatory components, like AF.  Elevation of CRP in these diseases is usually associated with increased disease burden and worse disease outcome.  In this study, we will evaluate the effect of selectively lowering CRP on the severity of AF in patients who are prone to frequent and unpredictable AF events.  By selectively lowering CRP with ISIS-CRPRx, we hope to observe a decrease in the frequency and duration of AF events in these patients," said Richard Geary , Ph.D., senior vice president of development at Isis. "ISIS-CRPRx is the first drug to be evaluated in clinical studies that can selectively reduce CRP.  In our Phase 1 studies, we observed selective, dose-dependent reduction of CRP in healthy volunteers.  Our Phase 2 program is designed to provide us with proof-of-concept data in diseases where elevated levels of CRP are predictive of severity of disease."

The Phase 2 study is a randomized, placebo-controlled, multiple-dose study evaluating the safety and efficacy of ISIS-CRPRx as a single agent in approximately 20 patients with AF who have pacemakers. The study is designed to evaluate the effects of ISIS-CRPRx on the frequency and duration of AF episodes. In addition to studying ISIS-CRPRx in AF, Isis is also currently evaluating ISIS-CRPRx in a Phase 2 study in patients with rheumatoid arthritis (RA), where CRP is chronically elevated. Top-line data from the Phase 2 RA study is planned for the middle of this year.

"ISIS-CRPRx is the first drug to test the hypothesis that lowering CRP levels could produce therapeutic benefit to patients. Although we are currently only evaluating ISIS-CRPRx in patients with rheumatoid arthritis and AF, if we are successful in demonstrating a significant benefit to lowering CRP in one or both of these diseases, there is a significant potential for ISIS-CRPRx to have broad application in numerous diseases with large commercial opportunity," concluded Lynne Parshall , chief operating officer at Isis.

ABOUT ISIS-CRPRx
ISIS-CRPRx­ is an antisense drug that is designed to inhibit the production of C-reactive protein (CRP).  For many years, CRP has been used as a clinical biomarker of diseases with an inflammatory component, such as cardiovascular disease, Crohn's disease, RA and end-stage renal disease.  Elevated levels of CRP have been linked to coronary artery disease and a growing body of evidence from clinical trials implicated CRP in cardiovascular disease progression.  Although CRP's active participation in these diseases remains to be determined, several lines of evidence support a causal role of CRP in disease, suggesting that it may be therapeutically beneficial to decrease CRP levels. 

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS-CRPRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
2. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
5. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
6. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
7. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
8. Webcast Alert: Isis Pharmaceuticals 2012 Financial Results and Highlights Conference Call
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
10. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
11. Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 23, 2017  Mirabilis Medical, a ... for non-invasive surgery, announced today CE Mark authorization ... of uterine fibroids throughout the European Union.  The ... from the US Food and Drug Administration to ... in the United States.  The Mirabilis System combines ...
(Date:3/23/2017)... Research and Markets has announced the addition ... Forecast to 2025" report to their offering. ... The Global Cryostat Market is ... next decade to reach approximately $3.5 billion by 2025. ... the given segments on global as well as regional levels presented ...
(Date:3/23/2017)... 23, 2017  Transportation Insight, a multi-modal lead logistics ... chain management firm with expertise serving clients in the ... Rick Zaffarano was named a 2017 Food ... by the only publication exclusively dedicated to covering the ... "Rick has brought to Transportation Insight a ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... stories about real people of God in congregations across the United States. ... Presbyterian minister ordained in 1964 who has served congregations in seven states throughout ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The physicians ... location in the greater Houston Area. The new location is located at 2255 E. ... Hospital in Springwoods Village. This newest location will provide patients living in the north ...
(Date:3/23/2017)... TX (PRWEB) , ... March 23, 2017 , ... ... clinic, located at 960 Gruene Road in Building 2. The clinic is the group’s ... Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things full ...
(Date:3/23/2017)... Minneapolis, MN (PRWEB) , ... March 23, 2017 , ... ... with internet and WiFi connectivity are making a huge impact on businesses and individual ... Global Institute estimates the IoT will have a value anywhere from $4 trillion to ...
Breaking Medicine News(10 mins):